Signaling by integrin receptors (original) (raw)
- Review Article
- Published: 22 September 1998
Review Article
Oncogene volume 17, pages 1365–1373 (1998)Cite this article
- 3489 Accesses
- 232 Citations
- Metrics details
Abstract
Adhesive interactions are critical for the proliferation, survival and function of all cells. Integrin receptors as the major family of adhesion receptors have been the focus of study for more than a decade. These studies have tremendously enhanced our understanding of the integrin-mediated adhesive interactions and have unraveled novel integrin functions in cell survival mechanisms and in the activation of divergent signaling pathways. The signals from integrin receptors are integrated from those originating from growth factor receptors in order to organize the cytoskeleton, stimulate cell proliferation and rescue cells from matrix detachment-induced programmed cell death. These functions are critical in the regulation of multiple processes such as tissue development, inflammation, angiogenesis, tumor cell growth and metastasis and programmed cell death.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Department of Tumor Biology, Schering-Plough Research Institute, Kenilworth, 07033, 2015, Galloping Hill Road, New Jersey, USA
C Chandra Kumar
Authors
- C Chandra Kumar
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Kumar, C. Signaling by integrin receptors.Oncogene 17, 1365–1373 (1998). https://doi.org/10.1038/sj.onc.1202172
- Published: 22 September 1998
- Issue Date: 17 September 1998
- DOI: https://doi.org/10.1038/sj.onc.1202172